POPULARITY
8 episodes with doebele
8 episodes with doebele
In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics about NTKR gene fusions, including recent and emerging breakthrough therapies.
I speak today to a former collegiate swimmer and co-founder of Rain Therapeutics, Dr. Robert Doebele. As the saying goes, "when one door closes, another door opens". This is how the story of Dr. Robert went for his collegiate swimming career. Which ends up with him winding his way around to the path that he's on today. After a time in academia he's left for more full-time work in private practice at Rain Therapeutics. Though I often think of the transition from one job to another as being jarring - Dr. Robert's story shows me how things can go much more smoothly with some planning ahead of time. Dr. Robert specializes in researching cures for very specific kinds of lung cancer. These solutions are often referred to as targeted therapies. We talk about the differences between the broad strokes of chemo and he explains to me how this "targeted therapy" works. If you need a little hope for the future then listen to my conversation with Dr. Robert Doebele and know that there are great people working on creating a brighter future for humanity.
"Bach is certainly one of the greatest Lutheran composers ever. However, there are many who think he was not just musician and composer, but equal parts theologian. The main ways he embedded theology into music were through word painting and cross and number symbolism. Bach always signed his manuscripts, SDG "Soli Deo Gloria" to God alone be the glory. The embedded symbolism was intended for God." Dr. Alexa Doebele is associate professor of music and Director of Choral Activities at Concordia University Wisconsin, where she conducts three choirs in addition to teaching undergraduate and graduate courses in music education, conducting, and choral literature. She is a frequent clinician, adjudicator, and guest conductor, and is active as an editor of choral music. Prior to her arrival in Wisconsin, Dr. Doebele served as the Director of Music at Holy Cross Lutheran Church in Wheat Ridge, Colorado. Her research interests intersect with her faith life through her study of the choral music of J. S. Bach and William Byrd. She is also active as both a solo and choral singer, most recently with Vox Antiqua, an early music ensemble for which she was also the artistic director, and previously with the Milwaukee Choral Artists, the Colorado Conductors' Chorus, and the Ars Nova Singers. She completed a bachelor's degree (double major in vocal performance and German language and literature) at Washington University in St. Louis and her Master of Music Education and Doctor of Musical Arts degrees at the University of Colorado. To learn more about Holden Village, visit: www.holdenvillage.org or to listen to more audio recordings visit: http://audio.holdenvillage.org The Holden Village Podcast is accessible through Apple iTunes, Google Play Music, Spotify, TuneIn, iHeart Radio, and most podcast apps. To contact the podcast author, podcast@holdenvillage.org
In this episode, Connie Doebele, C-SPAN Center Managing Director, talks about C-SPAN, the C-SPAN Center, the C-SPAN Archives, Brian Lamb and more.Â
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Robert C Doebele, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.
Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.Â
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.Â
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.Â
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
© 2020-2025 Ivy Podcast Discovery LLC
